NBIX — Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Market Cap

$13.30B

P/E Ratio

27.56

Beta

0.36

52-Week Range

84.23-160.18

Dividend Yield

$0.00

CEO

Kyle W. Gano

Employees

1,800

IPO Date

May 23, 1996

Exchange

NASDAQ